Axia Pharmaceutical Recalls Lidocaine HCL Injection Due to Sterility Concerns
Axia Pharmaceutical is recalling Lidocaine HCL Injection due to a lack of assurance of sterility. The product is distributed in the U.S., Puerto Rico, Barbados, and the Dominican Republic.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score under the rubric for significant injury or property damage reports or high-risk contamination.
Plain-English summary
Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical is recalling Lidocaine HCL (PF) Injection, 4% (PF) 40 mg/mL Injectable, 5 mL Single-use Vial. The recall is being conducted due to a lack of assurance of sterility.
The affected product is identified by Lot # 07012019+52569 with an expiration date of 3/15/2020. The NDC number is 71283-1011-5. This product is intended for ocular injection and is preservative-free.
The product was distributed nationwide in the U.S.A., as well as in Puerto Rico, Barbados, and the Dominican Republic. Healthcare providers and patients should stop using the affected product and contact the manufacturer or their healthcare provider for further instructions.
The recalled product
- Product
- Lidocaine HCL (PF) Injection, LIDOCAINE HCL 4% (PF) 40 MG/ML INJECTABLE, For ocular injection, Preservative free, discard unused portion, protect from light, 5 mL Single-use Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-1011-5
- Category
- Drug — Injectable
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 07012019+52569
- Exp 3/15/2020
Distribution
Part of a larger recall action
This product is one of 63 recalled by Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 63 products in this recall →Related recalls
Same manufacturer · Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
See all →- Severe
- SevereAxia Pharmaceutical Recalls Selenium Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- Severe
- SevereAxia Pharmaceutical Recalls Hydroxyprogesterone Caproate Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
- SevereAxia Pharmaceutical Recalls Alprostadil Injection Due to Sterility Concerns
FDA (Drugs) · 2020-03-11
Same hazard · sterility
See all →- SevereHouston Rx LLC Recalls Tirzepatide/Niacinamide Vials Due to Sterility Concerns
FDA (Drugs) · 2026-10-21
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
Similar recalls
- HighLidocaine-PF Injectable Vials Recalled for Sterility Assurance Deficiency
FDA (Drugs) · 2023-02-01
- SevereRXQ Compounding Recalls Lidocaine Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereBeacon Hill Medical Pharmacy Recalls Lidocaine Injectable Due to Sterility Concerns
FDA (Drugs) · 2013-09-18
- SevereRXQ Compounding Recalls Buffered Lidocaine HCL 1% Injection Solution
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Buffered Lidocaine HCL 1% Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14
- SevereRXQ Compounding Recalls Lidocaine HCL 2% Injection Due to Sterility Concerns
FDA (Drugs) · 2019-08-14